Evidence map›Paper›PMID 36691995›Full record

ArticleCancer communications (London, England)2023

A nanotherapeutic strategy to target drug-tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer.

Tatiana Shaurova, Lingyue Yan, Yafei Su, Laurie James Rich, Vui King Vincent-Chong, Hannah Calkins, Saraswati Pokharel, Martin Petkovich, Mukund Seshadri, Yun Wu and 1 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer communications (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Therapeutic advances of targeting receptor tyrosine kinases in cancer.Signal transduction and targeted therapy · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tatiana ShaurovaDepartment of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Lingyue YanDepartment of Biomedical Engineering, University at Buffalo, the State University of New York, Buffalo, New York, USA.
Yafei SuDepartment of Biomedical Engineering, University at Buffalo, the State University of New York, Buffalo, New York, USA.
Laurie James RichCell Stress and Biophysical Oncology Graduate Program, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Vui King Vincent-ChongDepartment of Oral Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Hannah CalkinsDepartment of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Saraswati PokharelDepartment of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Martin PetkovichCancer Research Institute, School of Medicine, Queens University, Kingston, Ontario, Canada.
Mukund SeshadriDepartment of Oral Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.ORCID 0000-0001-8729-9532
Yun WuDepartment of Biomedical Engineering, University at Buffalo, the State University of New York, Buffalo, New York, USA.ORCID 0000-0002-6926-777X
Pamela Anne HershbergerDepartment of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.ORCID 0000-0003-0030-6520

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Dean G. Tang · 1985 to 2026
$116.6M
Photoacoustic Micro-Imaging system for Shared Tumor Imaging Resource at Roswell PS10OD010393 · OD · ROSWELL PARK CANCER INSTITUTE CORP · PI SESHADRI, MUKUND · 2012 to 2012
$596k
NCI NIH HHS P30 CA016056NIH HHS S10 OD010393
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsErbB ReceptorsHumansTyrosine Kinase InhibitorsEGFR protein, humanErbB ReceptorsTyrosine Kinase Inhibitors

Identifiers

PMID36691995
PMCPMC10091104

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.